2.3. Study Design
voiding dysfunction
This study was a 12-week, randomized, double-blind, placebo-controlled trial conducted to assess the safety and efficacy of BRE against MCS and voiding dysfunction. A total of 30 subjects participated in the study, with 15 individuals assigned to the BRE and 15 to the placebo group. Subjects who met the selection criteria were assigned to the BRE group or placebo group based on an allocation code generated using a block-based random assignment method. 